Adicet Bio Grants Stock Options to New Hires at $0.72/Share

Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Very Positive)

Tags

08/29/2025 - 04:48 PM

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted inducement awards on August 29, 2025.

Two individuals were hired by Adicet in August 2025. In the aggregate, Adicet granted new hires non-qualified stock options to purchase 84,000 shares of Adicet鈥檚 common stock with an exercise price of $0.72 per share, the closing price of Adicet鈥檚 common stock as reported by Nasdaq on August 29, 2025. One-fourth of the shares underlying each employee鈥檚 option will vest on the one-year anniversary of each recipient鈥檚 start date and thereafter the remaining three-fourths of the shares underlying each employee鈥檚 option will vest in thirty-six substantially equal monthly installments, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of the recipient鈥檚 start date, in each case, subject to each such employee鈥檚 continued employment with Adicet on such vesting dates.

All of the above-described awards were granted outside of Adicet鈥檚 stockholder-approved equity incentive plans pursuant to Adicet鈥檚 2022 Inducement Plan (the Inducement Plan), which was adopted by the board of directors in January 2022 and subsequently amended in January 2023. The awards were authorized by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with Adicet in accordance with Nasdaq Listing Rule 5635(c)(4).

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of 鈥渙ff-the-shelf鈥� gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at .